Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult male or non-pregnant, non-lactating female aged between 40 and 80 years old, both inclusive.~2. Patient with a clinical diagnosis of stable moderate to severe COPD according to the GOLD classification~3. Current, or ex-cigarette smoker with a smoking history of at least 10 pack-years.~4. Patient whose FEV1 at the Screening Visit measured between 10-15 minutes post inhalation of 400 mcg of salbutamol is 30% FEV1 \<80% of the predicted normal value (i.e., 100 x Post-salbutamol \< FEV1/ Predicted FEV1 must be \< 80% and ≥ 30%).~5. Patient whose FEV1/FVC at the Screening Visit measured between 10-15 minutes post inhalation of 400 mcg of salbutamol is \< 70% (i.e., 100 x Post-salbutamol FEV1 /FVC \< 70%).~6. Patient who is eligible and able to participate in the trial and who consent to do so in writing after the purpose and nature of the investigation have been explained.~7. Patient whose COPD symptoms and FEV1 values at the time of randomisation are stable compared to the Screening Visit, according to the investigator's medical judgment~Exclusion Criteria:~1. History or current diagnosis of asthma or exercise-induced bronchospasm.~2. Clinically significant respiratory conditions at the time of Inform Consent signature~3. Hospitalisation due to COPD exacerbation within the previous 3 months.~4. Signs of a COPD exacerbation or respiratory infection (including the upper respiratory tract) within the previous 6 weeks.~5. Patient who has a resting systolic blood pressure ≥ 200 mmHg, a resting diastolic blood pressure ≥ 120 mmHg or a resting heart rate ≥ 105 bpm at screening visit.~6. Clinically significant cardiovascular conditions~7. Presence of symptomatic prostatic hypertrophy and/or bladder neck obstruction.~8. Presence of narrow-angle glaucoma.~9. QTc \[calculated according to Bazett's formulae (QTc=QT/RR1/2) above 470 milliseconds in the ECG performed at Screening Visit,~10. Patient who does not maintain regular day/night, waking/sleeping cycles

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Formoterol 12 μg (Type: ACTIVE_COMPARATOR): Formoterol fumarate 12 μg twice daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo twice daily
- Aclidinium 200 μg / formoterol 12 μg (Type: EXPERIMENTAL): Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) twice daily
- Aclidinium 200 μg / formoterol 6 μg (Type: EXPERIMENTAL): Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) twice daily
- Aclidinium 200 μg (Type: EXPERIMENTAL): Aclidinium bromide 200 μg twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).